Effect of glycemic control on diabetic retinopathy and diabetic macular edema: a prospective observational study
DOI:
https://doi.org/10.18203/2349-3933.ijam20210011Keywords:
Diabetic retinopathy, Diabetic macular oedema, Glycaemic control, Glycated haemoglobinAbstract
Background: The objective of the study was to examine the effect of long-term glycemic control, as measured by glycated hemoglobin levels (HbA1C), on the onset and progression of diabetic retinopathy (DR) and diabetic macular edema (DME) over a period of 10 years.
Methods: Patients who were diagnosed to have type 2 diabetes mellitus participated in this cross-sectional observational study. Duration of onset of diabetes and the glycemic control status were analyzed. Fasting and postprandial blood sugar levels and HbA1C levels were tested for every participant. Diabetic retinopathy was graded as per the ETDRS guidelines using stereoscopic fundus photographs. In addition to the clinical evaluation, optical coherence tomography was done to confirm the presence of DME.
Results: A total of 212 diabetic patients were enrolled in this study. One sixty-four patients (78.1%) had DR, out of which 71 patients (43.3%) had mild non proliferative diabetic retinopathy (NPDR), 42 patients (25.6%) had moderate NPDR, 31 patients (18.9%) had severe NPDR, and 20 (12.2%) had proliferative diabetic retinopathy (PDR). Fifty-nine patients with DR (36%) had DME. Duration of diabetes (14.62±6.18 vs 9.72±3.68 years, p<0.001), higher fasting blood glucose (176.79±59.13 vs 138.46±49.44 mg/dl, p<0.001) and higher HbA1c levels (8.21±1.38 vs 7.48±1.25 %, p=0.002) were significantly associated with DR.
Conclusions: The stage of diabetic retinopathy rather than metabolic status is a strong predictive factor for the development of diabetic macular edema.
References
Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H et al. Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet global health. 2013;1(6):e339-49.
DCCT Research Group. The Diabetes Control and Complications Trial (DCCT): design and methodologic considerations for the feasibility phase. Diabetes. 1986;35(5):530-45.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53.
Olafsdottir E, Andersson DK, Dedorsson I, Stefánsson E. The prevalence of retinopathy in subjects with and without type 2 diabetes mellitus. Acta Ophthalmologica. 2014;92(2):133-7.
Hainsworth DP, Bebu I, Aiello LP, Sivitz W, Gubitosi-Klug R, Malone J et al. Risk factors for retinopathy in type 1 diabetes: the DCCT/EDIC study. Diabetes care. 2019;42(5):875-82.
Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-22.
Voigt M, Schmidt S, Lehmann T, Köhler B, Kloos C, Voigt UA et al. Prevalence and progression rate of diabetic retinopathy in type 2 diabetes patients in correlation with the duration of diabetes. Exp Clin Endocrinol Diabetes. 2018;126(09):570-6.
Wat N, Wong RL, Wong IY. Associations between diabetic retinopathy and systemic risk factors. Hong Kong Med J. 2016;22(6):589-99.
Siegel D, Swislocki AL. The ACCORD Study: the devil is in the details. Metabolic Syndrome Related Disorders. 2010;9(2):81-4
De Faria JB, Silva KC, De Faria JM. The contribution of hypertension to diabetic nephropathy and retinopathy: the role of inflammation and oxidative stress. Hypertension Res. 2011;34(4):413-22.
Huang J. Commentary on Relation between BMI and Diabetes Mellitus and Its Complications among US Older Adults. Southern med j. 2015;108(1):37-8.
Zhou Y, Wang C, Shi K, Yin X. Relation of metabolic syndrome and its components with risk of diabetic retinopathy: A meta-analysis of observational studies. Med. 2018;97(38).
Cai X, Chen Y, Yang W, Gao X, Han X, Ji L. The association of smoking and risk of diabetic retinopathy in patients with type 1 and type 2 diabetes: a meta-analysis. PLoS One. 2019;14(1):e0210367.
Jeng CJ, Hsieh YT, Yang CM, Yang CH, Lin CL, Wang IJ. Diabetic retinopathy in patients with diabetic nephropathy: development and progression. PLoS One. 2016;11(8):e0161897.
Patel S, Chen H, Tinkham NH, Zhang K. Genetic susceptibility of diabetic retinopathy. Current diabetes reports. 2008;8(4):257-62.
Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Physical therapy. 2008;88(11):1254-64.
Bursell SE, Fonda SJ, Lewis DG, Horton MB. Prevalence of diabetic retinopathy and diabetic macular edema in a primary care-based teleophthalmology program for American Indians and Alaskan Natives. PLoS One. 2018;13(6):e0198551.
Solomon SD, Goldberg MF. ETDRS Grading of Diabetic Retinopathy: Still the Gold Standard?. Ophthalmic res. 2019;62(4):185-90.
Wilkinson CP, Ferris III FL, Klein RE, Lee PP, Agardh CD, Davis M et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmol. 2003;110(9):1677-82.
Gorst C, Kwok CS, Aslam S, Buchan I, Kontopantelis E, Myint PK et al. Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. Diabetes Care. 2015;38(12):2354-69.
Pinto MV, Rosa LC, Pinto LF, Dantas JR, Salles GF, Zajdenverg L et al. HbA1c variability and long-term glycemic control are linked to peripheral neuropathy in patients with type 1 diabetes. Diabetol Metabolic Syndrome. 2020;12(1):1-4.
Orsi E, Solini A, Bonora E, Fondelli C, Trevisan R, Vedovato M et al. Haemoglobin A1c variability is a strong, independent predictor of all‐cause mortality in patients with type 2 diabetes. Diabetes, Obesity Metabolism. 2018;20(8):1885-93.
Nordwall M, Arnqvist HJ, Bojestig M, Ludvigsson J. Good glycemic control remains crucial in prevention of late diabetic complications–the Linköping Diabetes Complications Study. Pediatr diabetes. 2009;10(3):168-76.
Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng j med. 1993;329(14):977-86.
Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Eng j med. 2008;358(24):2545-59.
